PRS44 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

Authors :: Adrian Martin
M. Schroeder
Dhvani Shah
Johnna Perdrizet
K Ndirangu
Nancy Risebrough
S. Mursleen
Source :: Value in Health. 21:S411
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: COPD
medicine.medical_specialty
business.industry
Health Policy
Inhaler
Public Health, Environmental and Occupational Health
Impact study
Cost-effectiveness analysis
medicine.disease
Societal perspective
medicine
In patient
Intensive care medicine
business

Full Text Access

Tools